Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for ...
The Food and Drug Administration will announce on Monday that it has sent over 2,200 letters pressing drug manufacturers, ...
An FDA review of records in the U.S. clinical trials database shows that results have not been reported for 30% of clinical ...
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers Data Anticipated in ...
An op-ed published by MedPage Today in 2023 that called for more aggressive enforcement of the data reporting law said the ...
PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...
Objective The multinational ERYTHRO ( NCT06046534) study investigated the experience of patients with moderate-to-severe SLE ...
Clinical Trials Arena on MSN
FDA cracks down on sponsor and researchers’ failure to publish trial data
The FDA has sent letters to more than 2,200 sponsors and investigators regarding more than 3,000 studies.
By combining our platform with Trialt’s expertise, we can support sponsors with both the technology and the operational ...
Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, ...
FDA officials said an internal analysis found results were not submitted for nearly 30% of studies “highly likely” to fall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results